Lavipharm

Lavipharm ROA

The Return on Assets (ROA) of Lavipharm (LAVI.AT) as of Oct 27, 2026 is 4.58 %. In the previous year, Return on Assets (ROA) was 7.15 % — a change of -35.86% (lower).

ROA

4.58 %

YoY

-35.86%

Last updated:

In 2025, Lavipharm's return on assets (ROA) was 4.58 %, a -35.86% increase from the 7.15 % ROA in the previous year.

The Lavipharm ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
2.98 EUR
Jan 1, 2019
10.68 EUR
Jan 1, 2020
4.14 EUR
Jan 1, 2021
3.25 EUR
Jan 1, 2022
0.73 EUR
Jan 1, 2023
1.63 EUR
Jan 1, 2024
7.15 EUR
Jan 1, 2025
4.58 EUR
The Lavipharm ROA history
YEARROAYoY
4.58 %-35.86%
7.15 %+338.68%
1.63 %+123.37%
0.73 %-77.57%
3.25 %-21.36%
4.14 %-61.28%
10.68 %+258.21%
2.98 %-89.64%
28.79 %+283.18%
7.51 %-187.49%
-8.59 %-72.41%
-31.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

ROA Details

Understanding Lavipharm's Return on Assets (ROA)

Lavipharm's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Lavipharm's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Lavipharm's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Lavipharm’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Lavipharm stock

Return on Assets (ROA) of Lavipharm is 4.58 % in 2025.

Return on Assets (ROA) of Lavipharm changed from 7.15 % to 4.58 %, representing a -35.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Lavipharm since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Lavipharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Lavipharm

All Key Metrics — Lavipharm